MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Balance Sheets Overview
Debt to Asset Ratio
15.77%
Unit: Dollar
Assets Breakdown
Cash and cash equivalents
Loan commitment fees
Grant receivable
Liabilities Breakdown
Additional paid-in capital
Accumulated deficit
Accounts payable
Common stock, 0.001 par value 75...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
9,041,570
10,354,773
11,627,849
Grant receivable
56,783
9,825
73,218
Prepaid expenses
175,413
170,771
261,439
Total current assets
9,273,766
10,535,369
11,962,506
Loan commitment fees
148,231
165,670
183,110
Total assets
9,421,997
10,701,039
12,145,616
Accounts payable
554,862
607,539
224,175
Accrued expenses
930,784
356,282
263,513
Total liabilities
1,485,646
963,821
487,688
Common stock, 0.001 par value 75,000,000 shares authorized and 41,084,731 shares issued and outstanding at december 31, 2025 and june 30, 2025
41,086
41,086
41,086
Additional paid-in capital
85,941,523
85,742,993
85,505,349
Accumulated deficit
-78,046,258
-76,046,861
-73,888,507
Total stockholders equity
7,936,351
9,737,218
11,657,928
Total liabilities and stockholders equity
9,421,997
10,701,039
12,145,616
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Cash and cash
equivalents
$9,041,570
Prepaid expenses
$175,413
Grant receivable
$56,783
Total current assets
$9,273,766
Loan commitment fees
$148,231
Total assets
$9,421,997
Total liabilities and
stockholders equity
$9,421,997
Total stockholders
equity
$7,936,351
Total liabilities
$1,485,646
Accumulated deficit
-$78,046,258
Additional paid-in capital
$85,941,523
Accrued expenses
$930,784
Accounts payable
$554,862
Common stock, 0.001 par
value 75,000,000...
$41,086
Buy us a coffee
Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc. (ANEB)